TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

IBSA

MetabolicOncologyImmunology
Specialty

IBSA is a specialty pharmaceutical company focused on Metabolic, Oncology, Immunology. Key products include TIROSINT-SOL.

2006
Since
5
Drugs
-
Trials
6
Approved (2yr)

Key Drugs

TIROSINT-SOL
levothyroxine sodium
Oncology
Thyroid hormone receptor 2 indications · 2016
VYBRIQUE
sildenafil citrate
PDE5 1 indications · 2025

Recent Activity

LIDOCAINE 2026-02-09
VYBRIQUE 2025-12-16
Type 3 - New Dosage Form
LIDOCAINE 2025-10-06
LIDOCAINE 2025-03-25
FLECTOR 2024-11-21
Labeling
LIDOCAINE 2024-06-18
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 41%
2 drugs Phase 1: 2
Oncology 35%
2 drugs
Immunology 24%
0 drugs Phase 3: 2

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Oncology, Immunology, Metabolic
Johnson & Johnson big-pharma
Oncology, Immunology, Metabolic
Sanofi big-pharma
Metabolic, Oncology, Immunology
Eli Lilly big-pharma
Metabolic, Oncology, Immunology
AstraZeneca big-pharma
Oncology, Metabolic, Immunology